Management options for follicular lymphoma: Observe; R-CHOP; B-R; Others?

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue SUPPL.1, 2011, Pages

  McLaughlin, Peter ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti CD20 monoclonal antibody therapy; Follicular lymphoma; Radioimmunotherapy

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; IBRITUMOMAB TIUXETAN; LENALIDOMIDE; MITOXANTRONE; OBINUTUZUMAB; PREDNISONE; RITUXIMAB; VINCRISTINE;

CANCER IMMUNOTHERAPY; CONFERENCE PAPER; DISEASE CONTROL; DISEASE FREE SURVIVAL; FAILURE FREE SURVIVAL; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; STEM CELL TRANSPLANTATION;

EID: 84858843458     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.04.006     Document Type: Conference Paper

References (59)

1. van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low grade lymphoma. Blood 1998; 92:1832-6.
2. Rohatiner AZS, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007; 25:2554-9.
3. Tsang RW, Gospodarowicz MK. Radiation therapy for localized low grade non-Hodgkin's lymphomas. Hematol Oncol 2005; 23:10-17.
4. Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma. Cancer 2010; 116:3797-3806.
5. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23:5019-26.
6. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M. D. Anderson Cancer Center. J Clin Oncol 2006; 24:1582-9.
7. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23:8447-52.
8. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination ofcyclophosphamide, doxorubicin, vincristine, and pred-nisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone. Blood 2005; 106:3725-32.
9. Buske C, Hoster E, Dreyling M, et al. Rituximab in combination with CHOP in patients with follicular lymphoma: analysis of treatment outcomes of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group after a follow up of 58 months. Blood 2008; 112 (suppl):901a (abstr 2599).
10. Herold M, Hess A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma. J Clin Oncol 2007; 25:1986-92.
11. Marcus R, Imre K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-23.
12. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26:4579-86.
13. Brice P, Bastion Y, Lepage E, et al. Comparison in low tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, on interferon alfa. J Clin Oncol 1997; 15:1110-7.
14. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas. J Clin Oncol 1998; 16:2332-8.
15. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma: the international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993; 329:987-94.
16. Lopez-Guillermo A, Montserrat E, Bosch F, et al. Applicability of the International Index for aggressive lymphomas to patients with low grade lymphoma. J Clin Oncol 1994; 12:1343-8.
17. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258-65.
18. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2. J Clin Oncol 2009; 27:4555-62.
19. Ardeshna KM, Qian W, Smith P, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asumptomatic, non-bulky follicular lymphoma (grades 1, 2, and 3a): a preliminiary analysis. Blood 2010; 116:5a (abstr 6).
20. Hainsworth J, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkins' lymphoma. J Clin Oncol 2005; 23:1088-95.
21. Kahl BS, Williams ME, Hong F, et al. Preliminary pharmacokinetic analysis of Eastern Cooperative Oncology Group protocol E4402: rituximab extended schedule or re-treatment trial (RESORT). Blood 2007; 110:1002a (abstr 3420).
22. Fowler N, McLaughlin P, Hagemeister FB, et al. A biologic combination of lena-lidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin's lymphoma. Blood 2009; 114:683a (abstr 1714).
23. 0 follicular lymphoma? Ann Oncol 1996; 7:713-8.
24. Petersen PM, Gospodarowicz M, Tsang R, et al. Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiatin therapy alone. J Clin Oncol 2004; 22 (suppl):563s (abstr 6521).
25. Mac Manus M, Hoppe R. Is radiotherapy curative for stage I and II low grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14:1282-90.
26. Wilder RB, Jones D, Tucker S, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiation Oncology Biol Phys 2001; 51:1219-27.
27. Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22:2654-61.
28. Vitolo U, Boccomini C, Ladetto M, et al. Rituximab maintenance versus observation after short term chemo-immunotherapy R-FND as first line treatment in elderly patients with advanced follicular lymphoma. Blood 2009; 114:680a (abstr 1706).
29. Gill S, Carney D, Ritchie D, et al. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol 2010; 21:331-4.
30. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national Lympho Care study. J Clin Oncol 2009; 27: 1202-8.
31. Morschhauser F, Mounier N, Sebban C, et al. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab- naïve, recurrent/refractory follicular non-Hodgkin lymphoma with a high tumor burden. Cancer 2010; 116:4299-4308.
32. Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530-6.
33. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas. Blood 2009; 114:168a (abstr 405).
34. Rohatiner AZS, Grergory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23:2215-23.
35. Cole BF, Solal-Celigny P, Gelber RD, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol 1998; 16:2339-44.
36. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation with yttrium-90 ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26:5156-64.
37. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab iodine I-131 tositumomab for previously untreated fol-licular non-Hodgkin's lymphoma. J Clin Oncol 2006; 24:4143-9.
38. McLaughlin P, Neelapu S, Fanale M, et al. R-FND followed by radioimmuno-therapy for high-risk follicular lymphoma. Blood 2008; 112:1050a (abstr 3056).
39. Gregory SA, Kassar M, Fung HC, et al. A prospective study evaluating the safety and efficacy of combination therapy with fludarabine plus mitoxantrone followed by yttrium-90 ibritumomab tiuxetan (Zevalin®) and maintenance rituximab s front line therapy for patients with intermediate or high risk follicular non-Hodgkin's lymphoma. Blood 2007; 110:409a (abstr 1360).
40. Gopal AK, Press OW, Wilbur SM, et al. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008; 112: 830-5.
41. Illidge TM, Bayne M, Brown NS, et al. Phase 1/2 study of fractionated 131-I rituximab in low grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009; 113:1412-21.
42. Kaminski MS, Tuck M, Estes J, et al. 131-I tositumomab therapy as initial treatment for follicular lymphoma. NEngl JMed 2005; 352:441-9.
43. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416-23.
44. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advance indolent lymphoma. J Clin Oncol 2009; 27:1607-14.
45. van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed-resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction. Blood 2006; 108:3295-3301.
46. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant jprolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxan-trone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas. Blood 2006; 108:4003-8.
47. Salles G, Seymour J, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immuno-chemotherapy. J Cin Oncol 2010; 28:15s (abstr 8004).
48. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377:42-51.
49. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adult (GELA). Blood 2006; 108:2540-4.
50. Al-Khabori MK, de Almeida J, Guyatt G, et al. High dose chemotherapy and autologous stem cell transplantation in the primary therapy of advanced follicular lymphoma in adults: a systematic review and meta-analysis of randomized clinical trials. Blood 2009; 114 (suppl):914a (abstr 2314).
51. Tarella C, Ladetto M, Benedetti F, et al. A recent update of three consecutive prospective trials with high-dose therapy and autograft, without or with rituximab, as primary treatment for advanced-stage follicular lymphoma shows a sizeable group of patients surviving in continuous complete remission up to 16 years after the end of treatment: should we still consider FL an incurable disease? Blood 2009; 114 (suppl):363a (abstr 882).
52. Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.JClin Oncol 2008; 26:211-7.
53. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves prdogressionn-free survival and survival in relapsed follicular non-Hodgkin's lyphoma: results from the randomized European CUP trial.J Clin Oncol 2003; 21:3918-27.
54. Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/or high-dose therapy with autotransplant at the time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008; 26:3614-20.
55. van Besien K. The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Reviews 2006; 20:235-44.
56. Hari P, Carreras J, Zhang M-J, et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14:236-45.
57. van Besien K. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematol Am Soc Hematol Educ Program; 2009:610-8.
58. Zarin DA, Tse T, Williams RJ, et al. The clinicalTrials.gov results database-update and key issues. N Engl J Med 2011; 364:852-60.
59. Lannutti BJ, Meadows SA, Herman SEM, et al. CAL-101, a p110S selective phos-phatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3Ksignaling and cellular viability. Blood 2011; 117:591-4.